Bridgeway Capital Management’s Cardlytics CDLX Stock Holding History

Bridgeway Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,576	Closed	-$79.5K	–	1248
2026 Q1	$79.5K	Hold	7,576	–	–	﹤0.01%	1151
2025 Q4	$87.1K	Sell	7,576 -2,624	-26%	-$40.5K	﹤0.01%	1142
2025 Q3	$248K	Buy	10,200 +5,000	+96%	+$83.3K	0.01%	973
2025 Q2	$85.5K	Hold	5,200	–	–	﹤0.01%	1094
2025 Q1	$94.6K	Sell	5,200 -6,000	-54%	-$171K	﹤0.01%	1045
2024 Q4	$416K	Buy	+11,200	New	+$429K	0.01%	853
2024 Q2	–	Sell	-4,216	Closed	-$611K	–	1279
2024 Q1	$611K	Sell	4,216 -1,500	-26%	-$127K	0.01%	870
2023 Q4	$526K	Sell	5,716 -1,584	-22%	-$161K	0.01%	925
2023 Q3	$1.2M	Hold	7,300	–	–	0.03%	656
2023 Q2	$461K	Buy	+7,300	New	+$442K	0.01%	924

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $122M AUM 11.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Bridgeway Capital Management's CDLX Position: Q2 2026 in Review

Bridgeway Capital Management sold out of Cardlytics (CDLX) in Q2 2026, closing a stake of 7,576 shares — an estimated $79.5K sold.

Bridgeway Capital Management first reported a position in CDLX in Q2 2023 and held it in 10 quarters. The position peaked at $1.2M in Q3 2023. 42 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.

Bridgeway Capital Management reported no remaining Cardlytics position as of Q2 2026 after selling out during the quarter.
Bridgeway Capital Management sold 7,576 Cardlytics shares in Q2 2026, an estimated $79.5K.
Bridgeway Capital Management first reported a position in Cardlytics in Q2 2023 and held it in 10 quarters.
Bridgeway Capital Management's Cardlytics position peaked at $1.2M in Q3 2023.
42 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.